Nycomed and Almirall announce commercialization agreement for roflumilast in Spain
. - Roflumilast is the first oral anti-inflammatory treatment for COPD patients, and has been developed by Nycomed - T…
. - Roflumilast is the first oral anti-inflammatory treatment for COPD patients, and has been developed by Nycomed - T…
. - Forest Laboratories acquires exclusive commercialisation rights to Daxas® in the United States in treatment of symp…
. - Forest Laboratories erwirbt die exklusiven Vermarktungsrechte für Daxas® in den USA zur Behandlung symptomatischer…
. - New drug application filed for United States - Treatment aimed at patients with symptomatic Chronic Obstructive Pu…
. - Marketing authorisation application filed for EU - Treatment aimed at patients with Chronic Obstructive Pulmonary…
. - Both 12-month pivotal studies in patients with symptomatic Chronic Obstructive Pulmonary Disease (COPD) meet primar…